IBDEI0S9 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28404,1,4,0)
 ;;=4^C74.92
 ;;^UTILITY(U,$J,358.3,28404,2)
 ;;=^5001319
 ;;^UTILITY(U,$J,358.3,28405,0)
 ;;=C44.112^^105^1380^12
 ;;^UTILITY(U,$J,358.3,28405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28405,1,3,0)
 ;;=3^Basal cell carcinoma of skin or right eyelid,including canthus
 ;;^UTILITY(U,$J,358.3,28405,1,4,0)
 ;;=4^C44.112
 ;;^UTILITY(U,$J,358.3,28405,2)
 ;;=^5001020
 ;;^UTILITY(U,$J,358.3,28406,0)
 ;;=C44.119^^105^1380^4
 ;;^UTILITY(U,$J,358.3,28406,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28406,1,3,0)
 ;;=3^Basal cell carcinoma of skin of left eyelid,including canthus
 ;;^UTILITY(U,$J,358.3,28406,1,4,0)
 ;;=4^C44.119
 ;;^UTILITY(U,$J,358.3,28406,2)
 ;;=^5001021
 ;;^UTILITY(U,$J,358.3,28407,0)
 ;;=C44.122^^105^1380^39
 ;;^UTILITY(U,$J,358.3,28407,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28407,1,3,0)
 ;;=3^Squamous cell carcinoma of skin of right eyelid,including canthus
 ;;^UTILITY(U,$J,358.3,28407,1,4,0)
 ;;=4^C44.122
 ;;^UTILITY(U,$J,358.3,28407,2)
 ;;=^5001023
 ;;^UTILITY(U,$J,358.3,28408,0)
 ;;=C44.129^^105^1380^33
 ;;^UTILITY(U,$J,358.3,28408,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28408,1,3,0)
 ;;=3^Squamous cell carcinoma of skin of left eyelid,including canthus
 ;;^UTILITY(U,$J,358.3,28408,1,4,0)
 ;;=4^C44.129
 ;;^UTILITY(U,$J,358.3,28408,2)
 ;;=^5001024
 ;;^UTILITY(U,$J,358.3,28409,0)
 ;;=C44.222^^105^1380^40
 ;;^UTILITY(U,$J,358.3,28409,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28409,1,3,0)
 ;;=3^Squamous cell carcinoma of skin of right ear/external auric canal
 ;;^UTILITY(U,$J,358.3,28409,1,4,0)
 ;;=4^C44.222
 ;;^UTILITY(U,$J,358.3,28409,2)
 ;;=^5001035
 ;;^UTILITY(U,$J,358.3,28410,0)
 ;;=C44.229^^105^1380^34
 ;;^UTILITY(U,$J,358.3,28410,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28410,1,3,0)
 ;;=3^Squamous cell carcinoma of skin of left ear/external auric canal
 ;;^UTILITY(U,$J,358.3,28410,1,4,0)
 ;;=4^C44.229
 ;;^UTILITY(U,$J,358.3,28410,2)
 ;;=^5001036
 ;;^UTILITY(U,$J,358.3,28411,0)
 ;;=C44.212^^105^1380^9
 ;;^UTILITY(U,$J,358.3,28411,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28411,1,3,0)
 ;;=3^Basal cell carcinoma of skin of right ear/external auric canal
 ;;^UTILITY(U,$J,358.3,28411,1,4,0)
 ;;=4^C44.212
 ;;^UTILITY(U,$J,358.3,28411,2)
 ;;=^5001032
 ;;^UTILITY(U,$J,358.3,28412,0)
 ;;=C44.219^^105^1380^3
 ;;^UTILITY(U,$J,358.3,28412,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28412,1,3,0)
 ;;=3^Basal cell carcinoma of skin of left ear/external auric canal
 ;;^UTILITY(U,$J,358.3,28412,1,4,0)
 ;;=4^C44.219
 ;;^UTILITY(U,$J,358.3,28412,2)
 ;;=^5001033
 ;;^UTILITY(U,$J,358.3,28413,0)
 ;;=C92.40^^105^1381^21
 ;;^UTILITY(U,$J,358.3,28413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28413,1,3,0)
 ;;=3^Acute promyelocytic leukemia, not having achieved remission
 ;;^UTILITY(U,$J,358.3,28413,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,28413,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,28414,0)
 ;;=C92.50^^105^1381^18
 ;;^UTILITY(U,$J,358.3,28414,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28414,1,3,0)
 ;;=3^Acute myelomonocytic leukemia, not having achieved remission
 ;;^UTILITY(U,$J,358.3,28414,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,28414,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,28415,0)
 ;;=C92.00^^105^1381^15
 ;;^UTILITY(U,$J,358.3,28415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28415,1,3,0)
 ;;=3^Acute myeloblastic leukemia, not having achieved remission
 ;;^UTILITY(U,$J,358.3,28415,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,28415,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,28416,0)
 ;;=C92.51^^105^1381^17
 ;;^UTILITY(U,$J,358.3,28416,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28416,1,3,0)
 ;;=3^Acute myelomonocytic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,28416,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,28416,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,28417,0)
 ;;=C92.41^^105^1381^20
 ;;^UTILITY(U,$J,358.3,28417,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28417,1,3,0)
 ;;=3^Acute promyelocytic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,28417,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,28417,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,28418,0)
 ;;=C92.01^^105^1381^14
 ;;^UTILITY(U,$J,358.3,28418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28418,1,3,0)
 ;;=3^Acute myeloblastic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,28418,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,28418,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,28419,0)
 ;;=C92.02^^105^1381^13
 ;;^UTILITY(U,$J,358.3,28419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28419,1,3,0)
 ;;=3^Acute myeloblastic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,28419,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,28419,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,28420,0)
 ;;=C92.42^^105^1381^19
 ;;^UTILITY(U,$J,358.3,28420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28420,1,3,0)
 ;;=3^Acute promyelocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,28420,1,4,0)
 ;;=4^C92.42
 ;;^UTILITY(U,$J,358.3,28420,2)
 ;;=^5001803
 ;;^UTILITY(U,$J,358.3,28421,0)
 ;;=C92.52^^105^1381^16
 ;;^UTILITY(U,$J,358.3,28421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28421,1,3,0)
 ;;=3^Acute myelomonocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,28421,1,4,0)
 ;;=4^C92.52
 ;;^UTILITY(U,$J,358.3,28421,2)
 ;;=^5001806
 ;;^UTILITY(U,$J,358.3,28422,0)
 ;;=C92.10^^105^1381^28
 ;;^UTILITY(U,$J,358.3,28422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28422,1,3,0)
 ;;=3^Chronic myeloid leuk, BCR/ABL-positive, not achieve remis
 ;;^UTILITY(U,$J,358.3,28422,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,28422,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,28423,0)
 ;;=C92.11^^105^1381^29
 ;;^UTILITY(U,$J,358.3,28423,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28423,1,3,0)
 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
 ;;^UTILITY(U,$J,358.3,28423,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,28423,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,28424,0)
 ;;=C92.12^^105^1381^30
 ;;^UTILITY(U,$J,358.3,28424,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28424,1,3,0)
 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
 ;;^UTILITY(U,$J,358.3,28424,1,4,0)
 ;;=4^C92.12
 ;;^UTILITY(U,$J,358.3,28424,2)
 ;;=^5001794
 ;;^UTILITY(U,$J,358.3,28425,0)
 ;;=C92.20^^105^1381^22
 ;;^UTILITY(U,$J,358.3,28425,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28425,1,3,0)
 ;;=3^Atyp chronic myeloid leuk, BCR/ABL-neg, not achieve remis
 ;;^UTILITY(U,$J,358.3,28425,1,4,0)
 ;;=4^C92.20
 ;;^UTILITY(U,$J,358.3,28425,2)
 ;;=^5001795
 ;;^UTILITY(U,$J,358.3,28426,0)
 ;;=C92.21^^105^1381^23
 ;;^UTILITY(U,$J,358.3,28426,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28426,1,3,0)
 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
 ;;^UTILITY(U,$J,358.3,28426,1,4,0)
 ;;=4^C92.21
 ;;^UTILITY(U,$J,358.3,28426,2)
 ;;=^5001796
 ;;^UTILITY(U,$J,358.3,28427,0)
 ;;=C92.22^^105^1381^24
 ;;^UTILITY(U,$J,358.3,28427,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28427,1,3,0)
 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
 ;;^UTILITY(U,$J,358.3,28427,1,4,0)
 ;;=4^C92.22
 ;;^UTILITY(U,$J,358.3,28427,2)
 ;;=^5001797
 ;;^UTILITY(U,$J,358.3,28428,0)
 ;;=C92.30^^105^1381^57
 ;;^UTILITY(U,$J,358.3,28428,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28428,1,3,0)
 ;;=3^Myeloid sarcoma, not having achieved remission
 ;;^UTILITY(U,$J,358.3,28428,1,4,0)
 ;;=4^C92.30
 ;;^UTILITY(U,$J,358.3,28428,2)
 ;;=^5001798
 ;;^UTILITY(U,$J,358.3,28429,0)
 ;;=C92.31^^105^1381^56
 ;;^UTILITY(U,$J,358.3,28429,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28429,1,3,0)
 ;;=3^Myeloid sarcoma, in remission
 ;;^UTILITY(U,$J,358.3,28429,1,4,0)
 ;;=4^C92.31
 ;;^UTILITY(U,$J,358.3,28429,2)
 ;;=^5001799
 ;;^UTILITY(U,$J,358.3,28430,0)
 ;;=C92.32^^105^1381^55
 ;;^UTILITY(U,$J,358.3,28430,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28430,1,3,0)
 ;;=3^Myeloid sarcoma, in relapse
